ArticleJournal of clinical medicine2024
Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge.
Vered Richter et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this paperpooled itcites it